BRAF and neoplasm: Indeed, it turned out that although engineering of BRAF T529 gatekeeper mutations does confer vemurafenib resistance in vitro, these mutations have never been reported in tumor samples from BRAF inhibitor-resistant patients (Whittaker et al, 2010).